Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1
BREAST CANCER, vol.29, no.6, pp.1106-1120, 2022 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 29 Issue: 6
- Publication Date: 2022
- Doi Number: 10.1007/s12282-022-01391-9
- Journal Name: BREAST CANCER
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Page Numbers: pp.1106-1120
- Keywords: FOXM1, Serotonin, 5-HT7 receptor, Metergoline, Breast cancer
- Open Archive Collection: AVESIS Open Access Collection
- Erciyes University Affiliated: Yes
Abstract
Background Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer and associated with poor prognosis and shorter survival due to significant genetic heterogeneity, drug resistance and lack of effective targeted therapeutics. Therefore, novel molecular targets and therapeutic strategies are needed to improve patient survival. Serotonin (5-hydroxytryptamine, 5-HT) has been shown to induce growth stimulatory effects in breast cancer. However, the molecular mechanisms by which 5-HT exerts its oncogenic effects in TNBC still are not well understood.